Login to Your Account



Earnings Roundup

'Uceris' Coming: FDA Gives Santarus Nod for Colitis Drug

By Randy Osborne
Staff Writer

Wednesday, January 16, 2013
Beating the decision deadline by two days, the FDA cleared for marketing Santarus Inc.'s oral formulation of the corticosteroid budesonide, branded Uceris, for mild to moderate ulcerative colitis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription